This framework agreement relates to short- and long-acting Erythropietins. Total term of this contract: 48 months: a two-year maturity, twice tacitly renewable for one year each time.
Short-acting ErythropoietinsThis framework agreement relates to short- and long-acting Erythropietins.
Long-acting ErythropoietinsThis framework agreement relates to short- and long-acting Erythropietins.